Daunorubicin for Acute Lymphoblastic Leukemia

"Affirmative - clinicaltrials.gov reveals that this medical trial is actively enrolling participants. The study was initiated on May 8th 2020 and the most recent update occurred July 1st 2022; it seeks to enrol 10 patients from one site."

"The primary aim of this two-year trial is to evaluate the pro/anti-cancer cellular immune response in patients with relapsed or refractory acute leukemia upon targeted anthracycline treatment. Secondary objectives include exploring pharmacokinetic parameters such as time at maximum concentration, maximum concentration, and elimination half-life through serial daunorubicin level evaluations taken before infusion and at multiple intervals post administration."

"Presently, 104 studies are being conducted on Daunorubicin with 35 reaching the third phase. Houston is a major city for research related to this drug; however, 7437 medical centres across the United States of America are currently running trials."

"Primarily prescribed for lymphoma, daunorubicin can additionally be used to alleviate the symptoms of Ewing's tumor, newly diagnosed therapy-related acute myeloid leukemia, and ALL (acute lymphoblastic leukemia)."

"Although there is some evidence to suggest that Daunorubicin is safe, as this study has only reached Phase 2 trials and without any data backing efficacy yet, its safety rating was determined to be a score of 2."

"As indicated by the eligibility requirements, individuals must be between 1 year old and 21 years of age to partake in this clinical trial."

"Affirmative. The particulars posted on clinicaltrials.gov verify that this medical study, initially published on 8th May 2020, is actively accepting volunteers. 10 test subjects are necessary to be enrolled from a single institution."

"This particular trial is accommodating a maximum of 10 patients suffering from acute leukemia, aged between 1 and 21 years old. To be eligible for participation they must have received two prior therapeutic attempts that were ineffective or been in relapse more than once but unable to receive intensive care at the time of consent. Upfront therapies are allowed as well as pulse steroids lasting 5 days or less given during routine maintenance therapy."